From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Clinical data
Pronunciation/ælˈfjuːzsɪn/ al-FEW-zoh-sin
Trade namesUroxatral, others
  • AU: B2
Routes of
By mouth (tablets)
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding82–90%
MetabolismLiver (CYP3A4-mediated)
Elimination half-life10 hours
ExcretionFeces (69%) and Urine (24%)
  • (RS)-N-[3-[(4-Amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide
CAS Number
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard100.108.671 Edit this at Wikidata
Chemical and physical data
Molar mass389.456 g·mol−1
3D model (JSmol)
  • O=C(NCCCN(c2nc1cc(OC)c(OC)cc1c(n2)N)C)C3OCCC3
  • InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23) checkY

Alfuzosin, sold under the brand name Uroxatral among others, is a medication of the α1 blocker class. It is used to treat benign prostatic hyperplasia (BPH).[1]

As an antagonist of the α1 adrenergic receptor, it works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate.

Alfuzosin was patented in 1978 and approved for medical use in 1988.[2] It was approved in the US for BPH in 2003. In 2017, it was the 266th most commonly prescribed medication in the United States, with more than one million prescriptions.[3][4]

Side effects[edit]

The most common side effects are dizziness (due to postural hypotension), upper respiratory tract infection, headache, fatigue, and abdominal disturbances. Side effects include stomach pain, heartburn, and congested nose.[5] Adverse effects of alfuzosin are similar to that of tamsulosin with the exception of retrograde ejaculation.[6]


Alfuzosin should be used with caution in patients with severe chronic kidney disease, and should not be prescribed to patients with a known history of QT prolongation or those who are taking medications known to prolong the QT interval.


Alfuzosin contains a stereocenter and is therefore chiral. There are two enantiomeric forms, (R)-alfuzosin and (S)-alfuzosin. The drug is used as a racemate, (RS)-alfuzosin, a 1: 1 mixture of the (R)- and (S)-forms.[7]

Enantiomers of alfuzosin
Strukturformel des (R)-Enantiomers
CAS number: 123739-69-5
Strukturformel des (S)-Enantiomers
CAS number.: 123739-70-8

It is provided as the hydrochloride salt.

Brand names[edit]

It is marketed under the brand name Uroxatral and elsewhere under the tradenames Xat, Xatral, Prostetrol and Alfural.


  1. ^ Lepor H (August 2016). "Alpha-blockers for the Treatment of Benign Prostatic Hyperplasia". The Urologic Clinics of North America. 43 (3): 311–23. doi:10.1016/j.ucl.2016.04.009. PMC 2213889. PMID 27476124.
  2. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 455. ISBN 9783527607495.
  3. ^ "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
  4. ^ "Alfuzosin Hydrochloride - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.
  5. ^ "Alfuzosin". MedlinePlus. United States National Library of Medicine. April 15, 2016.
  6. ^ Liu C, Zeng G, Kang R, Wu W, Li J, Chen K, Wan SP (2015). "Efficacy and Safety of Alfuzosin as Medical Expulsive Therapy for Ureteral Stones: A Systematic Review and Meta-Analysis". PLOS ONE. 10 (8): e0134589. Bibcode:2015PLoSO..1034589L. doi:10.1371/journal.pone.0134589. PMC 4526635. PMID 26244843. This article incorporates text available under the CC BY 4.0 license.
  7. ^ Rote Liste Service GmbH (Hrsg.): Rote Liste 2017 - Arzneimittelverzeichnis für Deutschland (einschließlich EU-Zulassungen und bestimmter Medizinprodukte). Rote Liste Service GmbH, Frankfurt/Main, 2017, Aufl. 57, S. 159, ISBN 978-3-946057-10-9.

External links[edit]